This study found that risk factors such as low education, low income cut off, taking antidepressants, and low social support are all factors that contribute to the higher percentage of these population in developing PPDS. Specifically, indigenous mothers had the most risk factors then immigrant mothers with non-indigenous Canadian women being closer to the overall population. South America
A main issue surrounding PPD is the lack of study and the lack of reported prevalence that is based on studies developed in Western economically developed countries. In countries such as Brazil, Guyana, Costa Rica, Italy, Chile, and South Africa there is actually a prevalence of report, around 60%. In an itemized research analysis put a mean prevalence at 10-15% percent but explicitly stated that cultural factors such as perception of mental health and stigma could possibly be preventing accurate reporting. The analysis for South America shows that PPD occurs at a high rate looking comparatively at Brazil (42%) Chile (4.6-48%) Guyana and Colombia (57%) and Venezuela (22%). In most of these countries PPD is not considered a serious condition for women and therefore there is an absence of support programs for prevention and treatment in health systems. Specifically, in Brazil PPD is identified through the family environment whereas in Chile PPD manifests itself through suicidal ideation and emotional instability. In both cases most women feel regret and refuse to take care of the child showing that this illness is serious for both the mother and child.
Carbinoxamine is an antihistamine and anticholinergic agent. It is used for hay fever, vasomotor rhinitis, mild urticaria, angioedema, dermatographism and allergic conjunctivitis. Carbinoxamine is a histamine antagonist, specifically an H1-antagonist. The maleic acid salt of the levorotatory isomer is sold as the prescription drug rotoxamine. It was patented in 1947 and came into medical use in 1953. It was first launched in the United States by the McNeil Corporation under the brand name Clistin. Carbinoxamine is available in various countries around the world by itself, combined with decongestants such as pseudoephedrine, and also with other ingredients including paracetamol, aspirin, and codeine. Society and culture
In June 2006 the FDA announced that more than 120 branded pharmacy products containing carbinoxamine were being illegally marketed and demanded they be removed from the marketplace. This action was precipitated by twenty-one reported deaths in children under the age of two who had been administered carbinoxamine-containing products. Despite the fact that the drug had not been studied in this age group, a multitude of OTC preparations containing carbinoxamine were being marketed for infants and toddlers. At present, all carbinoxamine-containing formulations are approved only for adults or children ages 3 or older. Brand names
Brand names include Clistin, Palgic, Rondec, Rhinopront, Ryvent. See also
Carbinoxamine/pseudoephedrine
Tofenacin
Clemastine
Captodiamine


== References ==